​Bruker Adds Another 1.2 GHz NMR System in Switzerland, Stock Climbs 

Bruker Corporation’s BRKR 1.2 GHz Ascend Nuclear Magnetic Resonance (NMR) spectrometer has been accepted at the Swiss High-field NMR Facility, operated jointly by the University of Basel, ETH Zürich, and the University of Zürich. This state-of-the-art instrument will significantly enhance the research capabilities of several user groups, enabling advanced studies in structural biology and macromolecular analysis.The latest 1.2 GHz NMR from Bruker is placed at the University of Zürich, marking the second of its kind in Switzerland. The first one, located at ETH, is used to develop solid-state NMR techniques and to study materials and biological systems.After the announcement on Friday, Bruker shares gained 3.1%, finishing the session at $57. The latest development is expected to bolster the company’s BioSpin segment, which has been seeing strong demand across the academic, government and industrial research markets outside of China, as well as strong contributions from the new automation, software and services business. Accordingly, we expect the market sentiment surrounding the BRKR stock to remain positive surrounding this news.Bruker has a market capitalization of $8.64 billion. The Zacks Consensus Estimate projects the company’s 2024 revenues to increase by 13.1%. It delivered an average earnings beat of 5.3% in the trailing four quarters.The Swiss High-field NMR Facility has locations at Biozentrum Basel and the University of Zürich. The new 1.2 GHz NMR complements the existing 800 MHz NMR in Basel and other high-field NMRs for protein structure determination, measurement of protein dynamics, ligand binding studies, conformational fingerprinting and the analysis of protein-protein interactions. Zacks Investment Research Image Source: Zacks Investment ResearchA key representative at the University of Zürich stated that the 1.2 GHz NMR enables the study of G protein-coupled receptors (GPCRs) in greater detail to define dynamic behavior and conduct drug binding studies. The higher resolution and dispersion at 1.2 GHz enhance the study of interactions of drug candidates with GPCRs. Another spokesperson of Biozentrum Basel noted that the 1.2 GHz NMR allows us to study structures and dynamics of chaperone-client complexes at atomic resolution. These detailed descriptions will reveal biophysical laws governing chaperone function, with implications for neurodegenerative diseases, like Parkinson’s.Per a research report, the global NMR Spectroscopy market was valued at $760.7 million in 2023 and is expected to grow at a compound annual rate of 5.1% by 2030. Key factors driving the market growth include increasing funding & investment initiatives for NMR spectroscopy in biomedical research, the rising need for affordable generic medicines and the growing scope of NMR spectroscopy in non-healthcare sectors.This month, Bruker announced the launch of the Dimension Nexus atomic force microscope (AFM), its newest addition to the industry-le